advertisement
Journal of Ocular Pharmacology and Therapeutics 19
Showing records 1 to 19 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Lavik E
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Laties A
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye
Sharma M
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of Latanoprost
Yoo R
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
70115 Ocular Purine Receptors as Drug Targets in the Eye
Jacobson KA
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 534-547
70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye
Bhowmick R
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Kuehn MH
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Rich CC
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70115 Ocular Purine Receptors as Drug Targets in the Eye
Civan MM
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 534-547
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of Latanoprost
Choi YA
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Stoltz R
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70510 Change in Central Corneal Thickness After the Discontinuation of Latanoprost in Normal Tension Glaucoma-Change in Central Corneal Thickness After Stop of Latanoprost
Cho BJ
Journal of Ocular Pharmacology and Therapeutics 2017; 33: 57-61
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Shoffstall AJ
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
70243 Drug-Loaded Nanoparticles Embedded in a Biomembrane Provide a Dual-Release Mechanism for Drug Delivery to the Eye
Gappa-Fahlenkamp H
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 565-573
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Humbert V
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Atkins K; Dumitrescu AV
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Brickman C; McVicar W
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
70528 Sustained Delivery of Timolol Maleate for Over 90 Days by Subconjunctival Injection
Kwon YH
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 642-649
69659 A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers
Baumgartner RA
Journal of Ocular Pharmacology and Therapeutics 2016; 32: 548-554
